Biogen and TrimTech Partner on $411M Protein Degrader Deal for Neurodegenerative Diseases

By Dr. Zubair Khalid, DVM, MS, PhD ·

Biogen and TrimTech Partner on $411M Protein Degrader Deal for Neurodegenerative Diseases

Biogen has entered a collaboration with TrimTech Therapeutics worth up to $411 million to develop protein degraders targeting neurodegenerative diseases. TrimTech, based in Cambridge, U.K., will receive upfront and milestone payments under the agreement, which includes potential "biobucks" tied to development and commercial success.

The partnership focuses on applying TrimTech's protein degrader technology to create new therapies for conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Protein degraders are a class of molecules that tag disease-causing proteins for destruction by the cell's natural waste disposal system, rather than simply blocking their activity.

This deal is relevant to the life sciences because protein degradation represents a growing therapeutic approach for diseases where traditional small-molecule inhibitors have struggled. Neurodegenerative conditions are often driven by the accumulation of misfolded or toxic proteins, making degradation a logical strategy. Biogen, a major player in neurology, has been expanding its pipeline beyond its approved Alzheimer's drug Aduhelm. TrimTech's platform could offer a new way to target proteins that have been considered undruggable with conventional methods.

Source: original report

Related articles